NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) — Digital Currency X Technology Inc. (Nasdaq: DCX) (“DCX” or the “Company”), a digital asset treasury management company, today announced that it has entered into a securities purchase agreement (the “Agreement”) with certain investors for a private placement of an aggregate of US$700,000,000 of units of the Company (the “Units”). Each Unit consists of one Class A ordinary share, par value US$0.0001 per share (the “Ordinary Share”), and three warrants (the “Warrants”). The purchase price per Unit is US$2.11, and the Warrants have an exercise price of US$2.11 per share (subject to adjustment as set forth in the Warrants), are exercisable on or after June 24, 2026, and will expire three years after such date. The Company intends to use the proceeds from the private placement for working capital and general corporate purposes, including the continued execution of its digital asset treasury strategy and the expansion of its newly established AI cloud computing services business, further diversifying the Company’s revenue base.
Onex Partners and Co-Investors to Acquire AirSprint, Canada’s Leader in Fractional Jet Ownership
Founder, CEO and select shareholders to remain investors as AirSprint enters its next chapter of growth
Adobe Introduces Firefly Foundry to Support Custom AI Models for Enterprise Brand Consistency
San Jose, CA, USA, June 25, 2026 (GLOBE NEWSWIRE) — Adobe has announced Adobe Firefly Foundry, a new offering designed to support enterprise organizations seeking greater control over generative artificial intelligence workflows and brand-aligned content creation. The introduction of Adobe Firefly Foundry expands Adobe’s artificial intelligence ecosystem by enabling organizations to develop and manage custom models tailored to specific brand requirements, visual standards, and content production objectives.
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of $1.81 per share (the “Offering Price”), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR.
Insoluble Sulfur Market Size to Skyrocket USD 2.27 Billion by 2035 as EV Tire Demand Accelerates Growth | SNS Insider
U.S. Insoluble Sulfur Market Expected to Grow USD 0.40 Billion by 2035, While Europe Advances USD 0.53 Billion Driven by Premium Tire Manufacturing
THCA Pre-Rolls 2026: Exhale Wellness Reports Rising Demand for Ready-to-Smoke Hemp Pre-Rolls as Buyers Move Away From Loose Flower
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
LEIDEN, Netherlands & CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR or the Company), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced positive target engagement data from its ongoing Phase 1 clinical study evaluating AX-0810, the Company’s first investigational Axiomer RNA editing oligonucleotide (EON), in healthy volunteers.
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
New CAOT project to support internationally educated OTs in Canada
Ottawa, Ontario, June 25, 2026 (GLOBE NEWSWIRE) — A new national effort is underway to better support internationally educated occupational therapists (IEOTs) as they build their careers in Canada. The Canadian Association of Occupational Therapy (CAOT) is proud to announce the upcoming launch of The Canadian Hub for Internationally Educated Occupational Therapists: Your First Stop to OT Practice in Canada.
Pizza Has Gone Cold. Domino’s Is Still Worth a Look.
Formic Acid Market Size to Surpass USD 4.00 Billion by 2035 as Demand Grows Across Agriculture, Chemicals, and Pharmaceuticals | SNS Insider
U.S. Market Projected to Expand USD 0.76 Billion by 2035, While Europe Advances Toward USD 0.51 Billion on EU Antibiotic Ban and Industrial Demand
Form 8.5 (EPT/RI) – Pharos Energy Plc
PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”
European Commission report supports cBrain’s expansion of environmental permitting activities in Europe
Nokia to provide intelligent connectivity for Finnish Border Guard counter-drone initiative nationwide
Press Release
Nokia to provide intelligent connectivity for Finnish Border Guard counter-drone initiative nationwide
The New Push to Ready Millions for AI Career Upheaval
Cloud Discovery Market Size to Surpass $9.77 Billion by 2035 as Multi-Cloud Adoption and Shadow IT Challenges Drive Enterprise Demand | Report by SNS Insider
The U.S. Cloud Discovery Market is Expected to Grow from $0.60 Billion in 2025 to $3.06 Billion by 2035, While Europe is Projected to Expand from $0.39 Billion to $1.42 Billion, Fueled by Rising Multi-Cloud Complexity, Strong Cloud Security Investments, and Regulatory Requirements Including GDPR, NIS2, and DORA Across Enterprise Environments
Breast Cancer Liquid Biopsy Market Size to Reach USD 3.42 Billion by 2035 | SNS Insider
The U.S. Breast Cancer Liquid Biopsy Market is projected to grow from USD 0.39 Billion in 2025 to USD 0.84 Billion by 2035, while Europe is expected to expand from USD 0.35 Billion to USD 0.78 Billion, driven by increasing companion diagnostic adoption, expanding precision oncology programs, and growing utilization of ctDNA testing.